-
-
-
-
-
-
-
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
-
-
-
-
-
-
-
Supernus Pharmaceuticals to Participate in September Investor Conferences
-
-
-
-
-
-
-
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
-
-
-
-
-
-
-
Supernus Announces Third Quarter 2022 Financial Results
-
-
-
-
-
-
-
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
-
-
-
-
-
-
-
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
-
1,177,378 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

